Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU-001: Gantenerumab and Solanezumab in Dominantly Inherited Alzheimer's Disease
NCT04623242Phase 3Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2012
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab and solanezumab in Alzheimer's disease (AD) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: DIAN-Multivariate Cognitive Endpoint at Week 260. Started Dec 2012; status: completed.
02
Drugs
gantenerumabsolanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04623242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623242.